Editorial

Updated Data for Brentuximab Vedotin Shows Durable Complete Remission and Manageable Toxicity

Updated data from a pivotal trial of single-agent brentuximab vedotin (adcetris™,Seattle Genetics) in patients with relapsed or refractory systemic...

Data on Brentuximab Vedotin Highlights Positive Findings and Clinically Meaningful Durations of Response

Data reported today demonstrating that prolonged treatment with Brentuximab Vedotin (SGN-35; Adcetris™, Seattle Genetics) beyond 16 cycles of therapy...

Antibody-drug Conjugate for MBC Highlights Importance of Personalised Approach to Cancer Care

Results of the first randomized phase II study, known as TDM4450g, in patients with previously untreated HER2-positive metastatic breast cancer...

Majority of Pediatric Patients with Hodgkin Lymphoma Achieve CR After Treatment with Brentuximab

Six out of nine pediatric patients with relapsed or refractory Hodgkin lymphoma (HL) (n=5)or systemic anaplastic large cell lymphoma...

European Medicines Agency Accepts Brentuximab Marketing Authorization Application

European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for brentuximab vedotin (Adcetris™, Takeda...

Novel Drugs Breaks Down Barriers – Attacks Breast Cancer Cells from Inside Out

Throwing stones at castle walls is one way to attack an enemy, but sneaking inside makes the target much...

Sanofi-Aventis In-licenses Therapeutic Antibody for the Treatment of Solid Cancers From Oxford BioTherapeutics’ –...

Earlier this month French pharmaceutical giant Sanofi-aventis acquired an exclusive world-wide license to one of Oxford BioTherapeutics’ internal preclinical...

Pfizer and Seattle Genetics Agree on Antibody-Drug Conjugate Collaboration

Pfizer and Seattle Genetics, a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for...

Brentuximab Offers Promising New Treatment Option for Patients with Relapsed or Refractory HL and...

While 70 to 80% of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy...

Phase I Trial of Loaded Antibody Establishes Dose, Catalogues Side Effects and Hints at...

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or...